Sunday, 27 Jul 2025
  • About us
  • Contact
  • History
  • My Interests
  • Privacy Policy
Nexpressdaily.com
  • Home
  • Politics
  • Finance
  • Health
  • Technology
  • Travel
  • World
  • 🔥
  • Technology
  • World
  • Finance
  • Politics
  • Travel
  • Health
Font ResizerAa
Nexpressdaily.comNexpressdaily.com
  • My Saves
  • My Interests
  • My Feed
  • History
  • Travel
  • Finance
  • Politics
  • Health
  • Technology
  • World
Search
  • Pages
    • Home
    • Blog Index
    • Contact Us
    • Search Page
    • 404 Page
  • Personalized
    • My Feed
    • My Saves
    • My Interests
    • History
  • Categories
    • Finance
    • Politics
    • Technology
    • Travel
    • Health
    • World
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Finance

May 27, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATNM

Nexpressdaily
Last updated: May 2, 2025 7:23 am
Nexpressdaily
Share
SHARE

NEW YORK, NY / ACCESS Newswire / May 1, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=146497&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Actinium Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company’s data from the Phase 3 Sierra
trial was unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s targeted radiotherapy, Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial’s poor OS data were unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Actinium stock during the relevant time frame – even if you still hold your shares – go to https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=146497&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire

Share This Article
Email Copy Link Print
Previous Article What Trump Has Done on Reproductive Health Care In 100 Days
Next Article Trump’s pick for top prosecutor in DC is testing Republican loyalty

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
InstagramFollow
LinkedInFollow
MediumFollow
QuoraFollow
- Advertisement -
Ad imageAd image

Popular Posts

HHS Report Urges “Exploratory Therapy” for Transgender Youth

The U.S. Department of Health and Human Services (HHS) released a report on Thursday, May…

By Nexpressdaily

Supreme Court denies challenges to bans on assault-style weapons and high-capacity magazines

WASHINGTON — The Supreme Court on Monday declined to hear two major gun cases challenging a Maryland…

By Nexpressdaily

Your PS5 now natively accepts Apple Pay

As first reported by , PS5 users now have a direct way to buy games…

By Nexpressdaily

You Might Also Like

Finance

India’s Licence Raj offers America important lessons

By Nexpressdaily
Finance

Elizabeth Warren targets price gouging and Trump tariffs in new bill

By Nexpressdaily
Finance

Keeping Seniors Safe, Connected, and Independent at Home with Arlo

By Nexpressdaily
Finance

Thomas Law Group, PC: Parental Alienation Family Attorney Report Released

By Nexpressdaily
Nexpressdaily.com
Facebook Twitter Youtube Rss Medium

About US

NexpressDaily.com is a leading digital news platform committed to delivering timely, accurate, and unbiased news from around the world. From politics and business to technology, sports, health, and entertainment – we cover the stories that matter most. Stay connected with real-time updates, expert insights, and trusted journalism, all in one place.

Top Categories
  • World
  • Finance
  • Politics
  • Tech
  • Health
  • Travel
Usefull Links
  • About us
  • Contact
  • History
  • My Interests
  • Privacy Policy

© Nexpressdaily. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?